| Title |
Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong)
|
|---|---|
| Published in |
Drug Design, Development and Therapy, August 2016
|
| DOI | 10.2147/dddt.s112873 |
| Pubmed ID | |
| Authors |
Jin-Sun Park, Joon-Han Shin, Taek-Jong Hong, Hong-Seog Seo, Wan-Joo Shim, Sang-Hong Baek, Jin-Ok Jeong, Youngkeun Ahn, Woong-Chol Kang, Young-Hak Kim, Sang-Hyun Kim, Min-Su Hyon, Dong-Hoon Choi, Chang-Wook Nam, Tae-Ho Park, Sang-Chol Lee, Hyo-Soo Kim |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Saudi Arabia | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 1% |
| Unknown | 67 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 12% |
| Student > Bachelor | 8 | 12% |
| Researcher | 6 | 9% |
| Student > Ph. D. Student | 6 | 9% |
| Student > Doctoral Student | 5 | 7% |
| Other | 9 | 13% |
| Unknown | 26 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 24% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 10% |
| Nursing and Health Professions | 4 | 6% |
| Environmental Science | 1 | 1% |
| Unspecified | 1 | 1% |
| Other | 7 | 10% |
| Unknown | 32 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 January 2021.
All research outputs
#4,841,279
of 25,394,764 outputs
Outputs from Drug Design, Development and Therapy
#304
of 2,270 outputs
Outputs of similar age
#82,092
of 381,115 outputs
Outputs of similar age from Drug Design, Development and Therapy
#8
of 76 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,270 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 381,115 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 76 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.